A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.
A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.
复制标题
一种新定义的超级增强子相关基因特征可预测弥漫性大 B 细胞淋巴瘤患者的预后
DOI：
10.3389/fgene.2022.827840
复制
发表时间：
2022
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
背景：弥漫性大B细胞淋巴瘤(DLBCL)是一种遗传异质性疾病，其生存结果可能有很大差异。各种强大的预后因素和模型已经被构建，然而，发展更准确的预后预测和靶向治疗DLBCL仍然面临挑战。对超级增强子(SE)相关基因的研究爆炸式增长，为癌症患者的预后提供了可能。在这里，我们的目标是利用DLBCL中的SE相关基因建立一种新的有效的预后模型。方法：本研究纳入基因表达总库中的1105例DLBCL患者，分为训练组和验证组。初步筛选出11个SE相关基因(BCL2、SPAG16、PXK、BTG1、LRRC37A2、EXT1、TGFBR2、ANKRD12、MYCBP2、PAX5和MYC)。最后，构建了基于这11个基因的风险评分模型。结果：Kaplan-Meier(K-M)曲线显示低风险组有较好的临床生存结果。通过时间相关的接收器工作特性(ROC)曲线确定了该模型的优良性能。进一步建立了基于多基因风险评分的诺模图，以促进可靠的预后预测。本研究认为SE相关基因风险特征可以有效地预测DLBCL患者的化疗反应。结论：建立了一种新的、可靠的SE相关基因标记，可以有效地将DLBCL患者按总体生存分为高危和低危两组，为临床治疗DLBCL提供依据。
Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease that can have profound differences in survival outcomes. A variety of powerful prognostic factors and models have been constructed; however, the development of more accurate prognosis prediction and targeted treatment for DLBCL still faces challenges. An explosion of research on super-enhancer (SE)–associated genes provide the possibility to use in prognostication for cancer patients. Here, we aimed to establish a novel effective prognostic model using SE-associated genes from DLBCL. Methods: A total of 1,105 DLBCL patients from the Gene Expression Omnibus database were included in this study and were divided into a training set and a validation set. A total of 11 SE-associated genes (BCL2, SPAG16, PXK, BTG1, LRRC37A2, EXT1, TGFBR2, ANKRD12, MYCBP2, PAX5, and MYC) were initially screened and identified by the least absolute shrinkage and selection operator (Lasso) penalized Cox regression, univariate and multivariate Cox regression analysis. Finally, a risk score model based on these 11 genes was constructed. Results: Kaplan–Meier (K–M) curves showed that the low-risk group appeared to have better clinical survival outcomes. The excellent performance of the model was determined via time-dependent receiver operating characteristic (ROC) curves. A nomogram based on the polygenic risk score was further established to promote reliable prognostic prediction. This study proposed that the SE-associated-gene risk signature can effectively predict the response to chemotherapy in DLBCL patients. Conclusion: A novel and reliable SE-associated-gene signature that can effectively classify DLBCL patients into high-risk and low-risk groups in terms of overall survival was developed, which may assist clinicians in the treatment of DLBCL.
影响因子：
3.7
作者：
Nagarkatti-Gude DR;Jaimez R;Henderson SC;Teves ME;Zhang Z;Strauss JF 3rd
通讯作者：
Strauss JF 3rd